Managing Pediatric Patients with Psoriasis
- 120 Downloads
Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. InEurope, etanercept has recently been approved for children aged 8 years and over. Data froma well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the initiation of treatment. Etanercept iswell tolerated; adverse effects are typically mild to moderate in severity. Early data from other biological agents are promising.
KeywordsPsoriasis Infliximab Etanercept Juvenile Rheumatoid Arthritis Plaque Psoriasis
Editorial assistance for the preparation of this manuscript was provided by Stephanie Blick of inScience Communications. This assistance was funded by Pfizer. The authors report no conflicts of interest.
- 5.EPARs for authorised medicinal products for human use. Enbrel. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrelM2.htm
- 12.FDA: CancerWarnings Required for TNF Blockers. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm